一种辅助病毒依赖型腺病毒载体的构建及其在小鼠体内 …

腺病毒载体具有在离体细胞和动物体内高效转移和表达外源基因的优点,但由于第一代腺病毒载体能在靶细胞内表达病毒结构蛋白,并诱导机体的细胞和体液免疫反应,影响了大体内的稳定表达。为了克服这一缺点,构建了一种辅助病毒依赖型腺病毒载体ＨＡｄＩ－ｈＦＶＩＩＩ。该载体去除了病毒基因组的ｌ３、Ｌ１、Ｌ２、ＶＡＩＶＡＩＩ、ｐＴＰ等基因序列。在第一代重组病毒ＡｄＩ－ｈＦＶＩＩＩ辅助下,能在２９３细胞包装和扩增。经氯化     

复制缺陷型腺病毒载体介导的人凝血因子Ⅷ基因在体内外的高效转移和表达

为了构建含人凝血因子Ⅷ基因的重组腺病毒载体系统,首先构建了含ＦⅧ（Ｂ结构域缺失型）的载体质粒ｐＡｄ－ｈＦⅧ和插入内含子结构的ｐＡｄＩ－ｈＦⅧ,经脂质体介导,证明两质粒的目的基因均能在ＣＯＳ－７细胞中表达有凝血活性的ＦⅧ因子,其中经纯化的载体质粒ｐＡｄ－ｈＦⅧ与ｐＢＨＧ１０经脂质体介导,共转染至２９３包装细胞,经同源重组和Ｅ１蛋白反式互补,形成Ｅ１／Ｅ３缺失型重组腺病毒载体颗粒Ａｄ－ｈＦⅧ．ＰＣＲ检则到病理２９３培养液上清的病毒ＤＮＡ中具有目的基因扩增片段,证明病毒ＤＮＡ含有ＦⅧ基因．经扩增、纯化、滴度测定,用于感染离体细胞ＣＯＳ－７、Ａ５４９、Ｌ９２９、２９３．证实该病毒能在上述细胞中高效转移和表达目的基因,其表达量具有一定范围内的剂量依赖性．ＣＯＳ－７细胞中,ＭＯＩ＞１０００时,有细胞毒效应,表达量反而下降．经耳缘静脉注射Ａｄ－ｈＦⅧ至家兔后,１～４周能测到一定水平的ＦⅧ蛋白,１周内升至最高峰．免疫组化研究表明感染的离体细胞和家兔肝等组织均有ＦⅧ表达,其中肝脏表达最高．为甲型血友病的基因治疗开辟了新途径     

微小腺病毒载体介导的人凝血IX因子小基因的离体表达

将带有内源内含子的人凝血ＩＸ因子ｃＤＮＡ（ｈＦＩＸ小基因）构建到不含腺病毒基因而只带有反向末端重复顺序（ＩＴＲ）和包装信号ψ等顺式元件的微小腺病毒（ｍｉｎｉ－ａｄｅｎｏｖｉｒｕｓ）载体ＧＴ２０７３上,得到载体ＧＴｉ’ＩＸ。将该载体与带有ｌａｃＺ报告基因的微小腺病毒载体ｐＲＰ１００１分别转移４入腺病毒馐细胞２９３Ｃｒｅ４中,随后专杂辅助病毒ＡｄＬＣ８,从而馐出微小腺病毒ＡｄＧＴｉ’ＩＸ和ＡｄＲＰ１０     

重组人干细胞因子在昆虫细胞中的高效表达

含信号肽的可溶性人干细胞因子（ｈＳＣＦ）ｃＤＮＡ 基因重组于杆状病毒转移载体ｐＶＬ９４１ 中,重组转移载体ｐＶＬ９４１ＳＣＦ与野生型苜蓿夜蛾核型多角体病毒（ＡｃＮＰＶ）ＤＮＡ 共转染草地夜蛾细胞Ｓｆ９ 后,通过体内同源重组构建了重组病毒ＡｃＮＰＶＳＣＦ。Ｓｏｕｔｈｅｒｎ 杂交表明重组病毒基因组中含有ｈＳＣＦ基因片段。重组病毒感染单层Ｓｆ９ 细胞后,表达产物分泌到胞外培养液中。用ＭＴＴ 比色法和ＴＦ１ 细胞株测定表达产物与ＩＬ３ 的协同效应,测得感染重组病毒的培养细胞第三天表达量为１９７０ ｕｎｉｔｓ／ｍ Ｌ培养液。Ｗｅｓｔｅｒｎｂｌｏｔｔｉｎｇ 分析可见分子量为１８ ×１０３ 、２０ ×１０３ 和２２ ×１０３ 三条带。     

人生长激素基因在昆虫细胞中的表达(英文)

近年发展起来的昆虫细胞－杆状病毒基因工程系统具有良好的优越性：（１）表达产量高,（２）产物的免疫原性、功能性类似于天然产物,（３）适用于悬浮及无血清培养。本实验中,将外源基因ｈＧＨ克隆至质粒ｐＶＬ１３９３,形成转移载体ｐＶＬ１３９３／ｈＧＨ（Ｆｉｇ．１＆２）。与昆虫核多角体病毒ＡｃＮＰＶ基因组ＤＮＡ共转染秋粘虫细胞Ｓｆ９（Ｆｉｇ．３）,ｐＶＬ１３９３／ｈＧＨ与ＡｃＮＰＶ基因组ＤＮＡ发生同源重组,取代多角体蛋白基因。经空斑分析纯化得到不含多角体,单一表达的重组病毒ｒＡｃＶｈＧＨ（Ｆｉｇ．４）,感染滴度达到２．０３ｘ１０８ＰＵＦ／ｍＬ。经反复实验,１０５细胞／ｍＬ感染６～７天后收获培养上清液,可得到表达量为４０μｇ／ｍＬ的ｈＧＨ蛋白（Ｆｉｇ．５,６＆７）。     

重组人GM—CSF基因在昆虫细胞中的表达

利用苜蓿夜蛾核型多角体病毒（ＡｃＮＰＶ）带β－Ｇａｌａｃｔｏｓｉｄａｓｅ基因标记的非融合蛋白基因转移载体ｐＢｌｕｅＢａｃ将人粒细胞巨噬细胞集落刺激因子（ｈＧＭ－ＣＳＦ）基因成功地插入病毒ＡｃＮＰＶ的基因组中．ｈＧＭ－ＣＳＦ基因在感染重组病毒的草地夜蛾（Ｓｐｏｄｏｐｔｅｒａｆｒｕｇｉｐｅｒｄａ）培养细胞Ｓｆ９中得到表达,感染后的Ｓｆ９细胞培养液能刺激人骨髓细胞在体外形成典型的集落,表达水平可达２．７×１０５５ＣＦＵ／ｍｌ。以ｈＧＭ－ＣＳＦ单抗所作的ＷｅｓｔｅｒｎＢｌｏｔｔｉｎｇ表明,表达的ｈＧＭ－ＣＳＦ对是３种糖基化程度不同的产物,分子量分别约为１５ｋｄ,１８ｋｄ和２０ｋｄ。     

胆固醇逆转运相关蛋白基因在骨骼肌的表达

构建载脂蛋白ＡＩ（ａｐｏＡＩ）、载脂蛋白Ｅ（ａｐｏＥ）和卵磷脂胆固醇酰基转移酶（ＬＣＡＴ）的病毒或非病毒载体,分别转染离体成肌细胞或直接注入小鼠骨骼肌,观察其表达程序及分泌人血等情况,探讨借用骨骼肌异源表达这些在胆固醇逆转运中起关键作用的重要候选基因,进而发展一种简易安全基因治疗方法的可能性。结果显示,质粒表达载体ｐＣＭＶａｐｏＥ３和重组腺病毒载体Ａｄ－ＲＳＶ－ａｐｏＡＩ在原代培养小鼠成肌细胞和成     

全反式维甲酸对HL-60细胞中N-乙酰氨基葡萄糖转移酶II,IV活力的影响

本文研究全反式视黄酸（ＡＴＲＡ）对ＨＬ－６０细胞中乙酰氨基葡萄糖转移酶ＩＩ和ＩＶ（ＧｎＴ－ＩＩ,ＩＶ）的调控作用,结果发现０．１μｍｏｌ／Ｌ的ＡＴＲＡ即可使ＧｎＴ－ＩＩ和ＩＶ的活力明显降低至５０％左右,但ＡＴＲＡ浓度增至１．０或１０μｍｏｌ／Ｌ时,酶活力不再显著下降。在未经ＡＴＲＡ处理的对照细胞中,培养不同时间两酶活力均有较大的变动,未经同步化和同步化的细胞分别在２４ｈ及至４８ｈ达到高峰。ＡＴＲＡ处理后,未经同步化细胞的酶活力高峰也在２４ｈ,但不论同步化与否,在２４ｈ之前均未见两酶活力的下降,２４ｈ后,酶活力逐步降低。对以上结果作了讨论。     

腺病毒载体介导的肝癌细胞专一性自杀基因表达

构建由肝癌细胞专一的ａｆｐ基因表达调节元件控制自杀基因ＨＳＶ－ｔｋ的穿梭质粒,将它与缺陷型腺病毒载体重组,得到ＡｄｒＡＦＰＴＫ病毒。经ＰＣＲ及Ｓｏｕｔｈｅｒｎ杂交等证实它们含ａｆｐ元件和ｔｋ基因。空斑形成试验表明病毒效价达１×１０１５ｐｆｕ／Ｌ。同时构建由ＣＭＶ启动子控制ｔｋ基因的类似载体作为对照。将这两个重组腺病毒分别感染ＡＦＰ阳性（ＨｅｐＧ２）或阴性（ＨｅＬａ,ＢＲＬ－３Ａ）细胞株（ｍ．ｏ．ｉ．＝１００）,以丙氧鸟苷（ｇａｎｃｉｃｌｏｖｉｒ,ＧＣＶ）处理后,用ＭＴＴ法测定杀伤细胞的效应。结果,ＡｄＣＭＶＴＫ感染这三种细胞后,ＧＣＶ半杀伤浓度分别为１．３、２、＜１μｍｏｌ／Ｌ;但是,ＡｄｒＡＦＰＴＫ感染的ＨｅＬａ和ＢＲＬ－３Ａ细胞的ＧＣＶ半杀伤浓度都＞１０００μｍｏｌ／Ｌ,而对ＨｅｐＧ２细胞只有＜１μｍｏｌ／Ｌ,表现出极高的细胞专一性。重组腺病毒ＡｄｒＡＦＰＴＫ可望用于肝癌的专一性基因治疗     

腺病毒介导的bak基因诱发肿瘤细胞的凋亡

构建了含ｂａｋ基因的转移载体ｐＣＡ１３－ｂａｋ,并用该载体和含有Ａｄ－５（人腺病毒５型）大部分基因组的重组质凿ｐＢＨＧ１１共转染２９３细胞（转化人胚肾细胞系）,分离并提纯缺陷型病毒Ａｄ－ｂａｋ。用该病毒感染ＨｅＬａ细胞（人宫颈癌细胞系）,相差显微镜、扫描电子显微镜直接观察到了典型的细胞凋亡形态,联蛋埃Ａｎｎｅｘｉｎ）Ｖ－ＦＩＯＴ７凋亡试剂盒检测到原本位于细胞３膜内侧的磷脂酰丝氨酸向外播转,进一步证     

Efficient generation and amplification of high-capacity adeno-associated virus/adenovirus hybrid vectors

Effective gene therapy is dependent on safe gene delivery vehicles that can achieve efficient transduction and sustained transgene expression. We are developing a hybrid viral vector system that combines in a single particle the large cloning capacity and efficient cell cycle-independent nuclear gene delivery of adenovirus (Ad) vectors with the long-term transgene expression and lack of viral genes of adeno-associated virus (AAV) vectors. The strategy being pursued relies on coupling the AAV DNA replication mechanism to the Ad encapsidation process through packaging of AAV-dependent replicative intermediates provided with Ad packaging elements into Ad capsids. The generation of these high-capacity AAV/Ad hybrid vectors takes place in Ad early region 1 (E1)-expressing cells and requires an Ad vector with E1 deleted to complement in trans both AAV helper functions and Ad structural proteins. The dependence on a replicating helper Ad vector leads to the contamination of AAV/Ad hybrid vector preparations with a large excess of helper Ad particles. This renders the further propagation and ultimate use of these gene delivery vehicles very difficult. Here, we show that Cre/loxP-mediated genetic selection against the packaging of helper Ad DNA can reduce helper Ad vector contamination by 99.98% without compromising hybrid vector rescue. This allowed amplification of high-capacity AAV/Ad hybrid vectors to high titers in a single round of propagation.     

Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy

The major complication in the treatment of hemophilia A is the development of neutralizing antibodies (inhibitors) against factor VIII (FVIII). The current method for eradicating inhibitors, termed immune tolerance induction (ITI), is costly and protracted. Clinical protocols that prevent rather than treat inhibitors are not yet established. Liver-directed gene therapy hopes to achieve long-term correction of the disease while also inducing immune tolerance. We sought to investigate the use of adeno-associated viral (serotype 8) gene transfer to induce tolerance to human B domain deleted FVIII in hemophilia A mice. We administered an AAV8 vector with either human B domain deleted FVIII or a codon-optimized transgene, both under a liver-specific promoter to two strains of hemophilia A mice. Protein therapy or gene therapy was given either alone or in conjunction with anti-CD20 antibody-mediated B cell depletion. Gene therapy with a low-expressing vector resulted in sustained near-therapeutic expression. However, supplementary protein therapy revealed that gene transfer had sensitized mice to hFVIII in a high-responder strain but not in mice of a low-responding strain. This heightened response was ameliorated when gene therapy was delivered with anti-murine CD20 treatment. Transient B cell depletion prevented inhibitor formation in protein therapy, but failed to achieve a sustained hypo-responsiveness. Importantly, use of a codon-optimized hFVIII transgene resulted in sustained therapeutic expression and tolerance without a need for B cell depletion. Therefore, anti-CD20 may be beneficial in preventing vector-induced immune priming to FVIII, but higher levels of liver-restricted expression are preferred for tolerance.     

Production of helper-dependent adenovirus vector relies on helper virus structure and complementing

Background

The helper‐dependent (HD) adenoviral (Ad) vector relies on a helper virus to provide viral proteins for vector amplification. HD‐Ad vectors can significantly increase therapeutic gene expression and improve safety. However, the yield of an HD‐Ad vector is generally lower than that of an E1‐deleted first‐generation vector, likely due to the alterations in viral E3 or packaging regions of a helper virus that attenuate its replication and complementing for an HD‐Ad vector.

Methods

To study this question and improve HD‐Ad vector production, we have generated four different helper viruses with a wild‐type or deleted E3 region, and with a relocated loxP. We have also constructed a first‐generation vector with a wild‐type E3 region and without the loxP site. We compared the replication of these viruses in Cre‐positive and ‐negative cells and studied their complementing for HD‐Ad vector production.

Results

Viruses with deleted E3 formed smaller plaques and produced lower titer compared with viruses containing the E3 region. The site where a loxP is inserted can also affect virus replication. Higher yield of HD‐Ad vector was obtained when a helper virus with wild‐type E3 was used. We also showed that deletion of the packaging signal in a helper virus through loxP/Cre interaction decreased the viral DNA complementing ability.

Conclusions

Although the E3 region is not essential for adenovirus replication in vivo, deletion of this region attenuates virus replication. Production of HD‐Ad vector can be further improved by modifications in helper virus structure. Copyright © 2002 John Wiley & Sons, Ltd.

     

Role of E4 in Eliciting CD4 T-Cell and B-Cell Responses to Adenovirus Vectors Delivered to Murine and Nonhuman Primate Lungs

Adenovirus vectors delivered to lung are being considered in the treatment of cystic fibrosis (CF). Vectors from which E1 has been deleted elicit T- and B-cell responses which confound their use in the treatment of chronic diseases such as CF. In this study, we directly compare the biology of an adenovirus vector from which E1 has been deleted to that of one from which E1 and E4 have been deleted, following intratracheal instillation into mouse and nonhuman primate lung. Evaluation of the E1 deletion vector in C57BL/6 mice demonstrated dose-dependent activation of both CD4 T cells (i.e., TH1 and TH2 subsets) and neutralizing antibodies to viral capsid proteins. Deletion of E4 and E1 had little impact on the CD4 T-cell proliferative response and cytolytic activity of CD8 T cells against target cells expressing viral antigens. Analysis of T-cell subsets from mice exposed to the vector from which E1 and E4 had been deleted demonstrated preservation of TH1 responses with markedly diminished TH2 responses compared to the vector with the deletion of E1. This effect was associated with reduced TH2-dependent immunoglobulin isotypes and markedly diminished neutralizing antibodies. Similar results were obtained in nonhuman primates. These studies indicate that the vector genotype can modify B-cell responses by differential activation of TH1 subsets. Diminished humoral immunity, as was observed with the E1 and E4 deletion vectors in lung, is indeed desired in applications of gene therapy where readministration of the vector is necessary.     

Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses

Background

Helper‐dependent, or gutted, adenoviruses (Ad) lack viral coding sequences, resulting in reduced immunotoxicity compared with conventional Ad vectors. Gutted Ad growth requires a conventional Ad to supply replication and packaging functions in trans. Methods that allow high‐titer growth of gutted vectors while reducing helper contamination, and which use safer helper viruses, will facilitate the use of gutted Ad vectors in vivo.

Methods

Replication‐defective helper viruses were generated that are deleted for Ad E1, E2b and E3 genes, but which contain loxP sites flanking the packaging signal. Complementing Ad packaging cell lines (C7‐cre cells) were also generated by transfecting 293 cells with the Ad E2b genes encoding DNA polymerase and pre‐terminal protein, and with a cre‐recombinase plasmid.

Results

We show that C7‐cre cells allow efficient production of gutted Ad using ΔE1 + ΔE2b + ΔE3 helper viruses whose growth can be limited by cre‐loxP‐mediated excision of the packaging signal. Gutted Ad vectors carrying ～28 kb cassettes expressing full‐length dystrophin were prepared at high titers, similar to those obtained with E2b+ helpers, with a resulting helper contamination of <1%.

Conclusions

These new packaging cell lines and helper viruses offer several significant advantages for gutted Ad vector production. They allow gutted virus amplification using a reduced number of passages, which should reduce the chances of selecting rearranged products. Furthermore, the residual helper contamination in gutted vector preparations should be less able to elicit immunological reactions upon delivery to tissues, since E2b‐deleted vectors display a profound reduction in viral gene expression. Copyright © 2002 John Wiley & Sons, Ltd.

     

A Helper-Independent Adenovirus Vector with E1, E3, and Fiber Deleted: Structure and Infectivity of Fiberless Particles

The adenovirus (Ad) fiber protein largely determines viral tropism through interaction with specific cell surface receptors. This molecule may also be involved in virion assembly or maturation, as some previously characterized fiber mutants were defective for processing of viral structural proteins. We previously described packaging cell lines that express Ad type 5 (Ad5) fiber and can complement the temperature-sensitive Ad fiber mutant H5ts142. We have now used these packaging cells to construct a new adenoviral vector (Ad5.βgal.ΔF) with E1, E3, and L5 (fiber) deleted and analyzed the fiber null phenotype. Ad5.βgal.ΔF growth was completely helper independent, and fiberless particles were produced by a single final round of growth in 293 cells. Cryoelectron microscopic studies and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis showed that the structure and composition of these particles was nearly identical to those of first-generation Ad vectors. As expected, fiberless particles had reduced infectivity on epithelial cells, but they retained the ability to infect monocytic cells via an integrin-dependent pathway. These studies provide a novel approach to developing retargeted Ad gene therapy vectors.     

Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted.

Although adenovirus vectors offer many advantages, it would be desirable to develop vectors with improved expression and decreased toxicity. Toward this objective, an adenovirus vector system with deletion of both the El and E2a regions was developed. A 5.9-kb fragment of the adenovirus type 5 (Ad5) genome containing the E2a gene and its early and late promoters was transfected into 293 cells. A complementing cell line, designated 293-C2, expressed the E2a mRNA and protein and was found to complement the defect in Ad5 viruses with temperature-sensitive or deletion mutations in E2a. A deletion of 1.3 kb removing codons 40 to 471 of the 529 amino acids of E2a was introduced into plasmids for preparation of viruses and vectors. An Ad5 virus with disruption of the El gene and deletion of E2a grew on 293-C2 cells but not on 293 cells. Vectors with E1 and E2a deleted expressing Escherichia coli beta-galactosidase or human alpha1-antitrypsin were prepared and expressed the reporter genes after intravenous injection into mice. This vector system retains sequences in common between the complementing cell line and the vectors, including 3.4 kb upstream and 1.1 kb downstream of the deletion. These vectors have potential advantages of increased capacity for insertion of transgene sequences, elimination of expression of E2a, and possibly reduction in expression of other viral proteins. Although the titers of the vectors with deleted are about 10- to 30-fold below those of vectors with E2a wild-type regions, the former vectors are suitable for detailed studies with animals to evaluate the effects on host immune responses, on duration of expression, and on safety.